Orthocell (ASX:OCC) Non Operating Income: A$1.88 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:OCC Orthocell Ltd ASX:OCC
61 GF Score
Price A$0.80
GF Value A$1.56
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Orthocell Non Operating Income?

Orthocell ASX:OCC +3.92% 61 Non Operating Income is A$1.88 Mil as of Dec. 2025. GuruFocus rates ASX:OCC with a GF Score™ of 61/100 and a GF Value™ of A$1.56 (Possible Value Trap). The stock has 1 warning sign investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Orthocell's Non Operating Income for the six months ended in Dec. 2025 was A$2.79 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.88 Mil.

Orthocell Non Operating Income Related Terms

Orthocell Non Operating Income Historical Data

* Premium members only.

The historical data trend for Orthocell's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orthocell Non Operating Income Chart

Orthocell Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.19 0.08 0.42 0.38

Orthocell Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 -0.93 1.29 -0.91 2.79
ASX:OCC
61GF Score
Orthocell Ltd ASX:OCC
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orthocell Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$1.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of A$1.88 Mil mean?
Orthocell (ASX:OCC) has a Non Operating Income of A$1.88 Mil as of Dec. 2025. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Orthocell and its competitors.
Is Orthocell's Non Operating Income too high?
Orthocell's current Non Operating Income is A$1.88 Mil. Overall, Orthocell has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orthocell's Non Operating Income compare to VRTX and REGN?
Orthocell's Non Operating Income of A$1.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Orthocell and its competitors. Orthocell's current Non Operating Income is A$1.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orthocell stock overvalued right now?
Based on GuruFocus' analysis, Orthocell (ASX:OCC) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.56, compared to a current price of A$0.80 — trading 49% below its estimated fair value. The current Non Operating Income is A$1.88 Mil. Orthocell's overall GF Score™ is 61/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Orthocell (ASX:OCC), the current Non Operating Income is A$1.88 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orthocell (ASX:OCC) Overvalued in 2026?

Based on GuruFocus' analysis, Orthocell stock appears to be undervalued. The current stock price of A$0.80 is trading 49% below its estimated GF Value™ of A$1.56. GuruFocus considers Orthocell to be Possible Value Trap.

Key valuation signals for ASX:OCC:

  • Non Operating Income: A$1.88 Mil
  • GF Value™: A$1.56 vs. price of A$0.80 (49% below fair value)
  • GF Score™: 61/100 with 1 warning sign

No single metric tells the full story. See the ASX:OCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orthocell Business Description

Address 90 South Street, Building 191, Murdoch University, Murdoch, Perth, WA, AUS, 6150
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir, which is a collagen wrap used in peripheral nerve repair; and OrthoACI, an implant used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline, such as Tendon Cell Therapy and Collagen Medical Device Platform.
61GF Score

Get the complete analysis for ASX:OCC

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.80
Price
A$1.56
GF Value